MBL2 and ovarian carcinoma: To date LC-MS-based quantitative proteomics analytical workflow allowed to discover several novel potential cancer biomarkers in serum/plasma for clinical application (reviewed by [15]): for instance, recently, altered protein abundances were found in non-Hodgkin lymphoma, infected or not by human immunodeficiency virus, (i.e., C1Q and B2M) [34]; predicted the outcome of breast cancer patients receiving neodiuvant chemotherapy (APOC3, MBL2, ENG and P4HB) [35] or associated with high risk of ovarian cancer in BRCA1/2 carriers (SPARC and THBS1) [20].